<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00379769</url>
  </required_header>
  <id_info>
    <org_study_id>BRL-049653/231</org_study_id>
    <nct_id>NCT00379769</nct_id>
  </id_info>
  <brief_title>RECORD: Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes</brief_title>
  <acronym>RECORD</acronym>
  <official_title>A Long Term, Open Label, Randomised Study in Patients With Type 2 Diabetes, Comparing the Combination of Rosiglitazone and Either Metformin or Sulfonylurea With Metformin Plus Sulfonylurea on Cardiovascular Endpoints and Glycaemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GlaxoSmithKline</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a phase 3b, multicentre, randomised, open label, parallel group study. A 4-week
      run-in period will be followed by a median of 6 years of treatment with study medication in
      addition to continuation of background glucose lowering therapy. Patients inadequately
      controlled on background metformin will be randomised to receive, in addition to metformin,
      either rosiglitazone or a sulfonylurea(glibenclamide, gliclazide or glimepiride) in a ratio
      of 1:1. Patients inadequately controlled on background SU will be randomised to receive, in
      addition to SU, either rosiglitazone or metformin in a ratio of 1:1. Equal numbers of
      patients receiving background metformin and SU at entry will be entered into the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A RECORD follow-up study is being performed to monitor the incidence of cancer and bone
      fractures in RECORD patients for a period of 4 years after the end of the main RECORD study
      (2008 - 2012).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2001</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">December 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as &quot;unknown deaths,&quot; but were counted as CV deaths for the analysis of this endpoint.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme &gt;= 2x the ULN or CK &gt; 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Cardiovascular Events and All-cause Deaths</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With CV/Microvascular Events</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Glycaemic Failure Events</measure>
    <time_frame>Baseline through to end of randomised dual therapy</time_frame>
    <description>Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Addition of Third Oral Agent/Switch to Insulin</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The Number of Participants Starting Insulin at Any Time During the Study</measure>
    <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
    <description>The number of participants starting insulin at any time during the study was recorded.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Change From Baseline in HbA1c at Month 60</measure>
    <time_frame>Baseline and Month 60 of randomised dual therapy treatment period</time_frame>
    <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
    <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
    <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
    <description>Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Change From Baseline in Body Weight at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Change From Baseline in Waist Circumference at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60</measure>
    <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
    <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Bone Fracture Event - Overall and by Gender: Main Study and Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Bone Fracture Event - Overall and by Gender: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined</measure>
    <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Bone Fracture Events With the Indicated Outcome: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up</measure>
    <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
    <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">4447</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>rosiglitazone in addition to background metformin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>rosiglitazone in addition to background sulfonylurea</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sulfonylurea in addition to background metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Metformin in addition to background sulfonylurea</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone</intervention_name>
    <description>Rosiglitazone maximum 8 mg per day</description>
    <arm_group_label>rosiglitazone in addition to background sulfonylurea</arm_group_label>
    <arm_group_label>rosiglitazone in addition to background metformin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sulfonylurea</intervention_name>
    <description>Sulfonylurea (SU) maximum permitted daily dose</description>
    <arm_group_label>Sulfonylurea in addition to background metformin</arm_group_label>
    <arm_group_label>Metformin in addition to background sulfonylurea</arm_group_label>
    <arm_group_label>rosiglitazone in addition to background sulfonylurea</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Metformin maximum permitted daily dose .</description>
    <arm_group_label>Sulfonylurea in addition to background metformin</arm_group_label>
    <arm_group_label>Metformin in addition to background sulfonylurea</arm_group_label>
    <arm_group_label>rosiglitazone in addition to background metformin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with type II diabetes mellitus as defined by 1999 World Health Organisation
             criteria.

          -  Glycated haemoglobin (HbA1c) &gt;7.0 % to = 9.0 % at visit 1.

          -  Use of an oral glucose lowering agent for a minimum of 6 months prior to screening and
             unchanged for 2 months prior to screening.

          -  Body mass index &gt;25.0 kg/m2.

        Exclusion Criteria:

          -  Patients receiving any other glucose lowering therapy which is not metformin or a
             sulfonylurea.

          -  Patients with systolic blood pressure &gt;180 mmHg or diastolic blood pressure &gt;105 mmHg.

          -  Patients who have required the use of insulin for glycaemic control at any time in the
             past.

          -  Hospitalisation for any major cardiovascular event in the last 3 months.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>GlaxoSmithKline</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Miranda</city>
        <state>New South Wales</state>
        <zip>2228</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Randwick</city>
        <state>New South Wales</state>
        <zip>2031</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wollongong</city>
        <state>New South Wales</state>
        <zip>2500</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carina Heights</city>
        <state>Queensland</state>
        <zip>4152</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kippa Ring</city>
        <state>Queensland</state>
        <zip>4021</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sherwood</city>
        <state>Queensland</state>
        <zip>4075</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Keswick</city>
        <state>South Australia</state>
        <zip>5035</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>North Adelaide</city>
        <state>South Australia</state>
        <zip>5006</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Port Lincoln</city>
        <state>South Australia</state>
        <zip>5606</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Antwerpen</city>
        <zip>2000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arlon</city>
        <zip>6700</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brussels</city>
        <zip>1090</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genk</city>
        <zip>3600</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kortrijk</city>
        <zip>8500</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Liège</city>
        <zip>4000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moerkerke</city>
        <zip>8340</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oostham</city>
        <zip>3945</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sint Gillis-Waas</city>
        <zip>9170</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilvoorde</city>
        <zip>1800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pleven</city>
        <zip>5800</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Plovdiv</city>
        <zip>4002</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1233</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1301</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1303</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1431/1000</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sofia</city>
        <zip>1606</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Varna</city>
        <zip>9010</zip>
        <country>Bulgaria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krapinske Toplice</city>
        <zip>49217</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rijeka</city>
        <zip>51000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Slavonski Brod</city>
        <zip>35000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Varaždin</city>
        <zip>42000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zagreb</city>
        <zip>10000</zip>
        <country>Croatia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brno</city>
        <zip>625 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ceske Budejovice</city>
        <zip>370 87</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Holice V Cechach</city>
        <zip>534 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hradec Kralove</city>
        <zip>500 05</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>377 38</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ostrava Poruba</city>
        <zip>708 52</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisek</city>
        <zip>397 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 2</city>
        <zip>128 42</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Praha 4</city>
        <zip>140 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rakovnik</city>
        <zip>269 01</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tabor</city>
        <zip>390 00</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trutnov</city>
        <zip>541 21</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aalborg</city>
        <zip>DK-9100</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aarhus</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Copenhagen</city>
        <zip>2300</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glostrup</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hilleroed</city>
        <zip>3400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koge</city>
        <zip>4600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kolding</city>
        <zip>DK-6000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>København NV</city>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Naestved</city>
        <zip>4700</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Odense C</city>
        <zip>DK-5000</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Silkeborg</city>
        <zip>8600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Slagelse</city>
        <zip>4200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paide</city>
        <zip>72714</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parnu</city>
        <zip>80018</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rakvere</city>
        <zip>44316</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saku</city>
        <zip>75501</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>10138</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>1162</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>11911</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tallinn</city>
        <zip>13415</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tartu</city>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Viljandi</city>
        <zip>71024</zip>
        <country>Estonia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02600</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Espoo</city>
        <zip>02710</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hanko</city>
        <zip>10900</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00150</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00810</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsinki</city>
        <zip>00930</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hyvinkaa</city>
        <zip>05800</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jyväskylä</city>
        <zip>40100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kerava</city>
        <zip>04200</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kuopio</city>
        <zip>70210</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lahti</city>
        <zip>15850</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lappeenranta</city>
        <zip>53100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oulun kaupunki</city>
        <zip>90015</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riihimäki</city>
        <zip>11130</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rovaniemi</city>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seinajoki</city>
        <zip>60220</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tampere</city>
        <zip>33100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20100</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Turku</city>
        <zip>20700</zip>
        <country>Finland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bully Les Mines</city>
        <state>Nord-Pas-de-Calais</state>
        <zip>62160</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Amilly</city>
        <zip>28300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Arras</city>
        <zip>62000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aspach le Bas 68700</city>
        <zip>68700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Aubagne</city>
        <zip>13400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Auchy les Hesdin</city>
        <zip>62770</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Azille</city>
        <zip>11700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beaumont Le Roger</city>
        <zip>21170</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beaumont sur Leze</city>
        <zip>31870</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belfort</city>
        <zip>90000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Belpech</city>
        <zip>11420</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Blotzheim</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bondy</city>
        <zip>93143</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>BP 1542 Dijon</city>
        <zip>21034</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Broglie</city>
        <zip>27270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Calmont</city>
        <zip>31560</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carbonne</city>
        <zip>31390</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carcassonne 11000</city>
        <zip>11000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carcassonne</city>
        <zip>11000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Carcassonne</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cassis</city>
        <zip>13260</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Castelnaudary</city>
        <zip>11400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Catelnaudary</city>
        <zip>11400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cernay</city>
        <zip>68700</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Champhol</city>
        <zip>28300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chartres</city>
        <zip>28000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corbeil Essonne</city>
        <zip>91014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coursan</city>
        <zip>11110</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cuincy</city>
        <zip>59553</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Danjoutin</city>
        <zip>90400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dessenheim</city>
        <zip>68600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dieppe</city>
        <zip>76200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dunkerque</city>
        <zip>59385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Epernon</city>
        <zip>28230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gemenos</city>
        <zip>13420</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hanches</city>
        <zip>28130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hautot sur Mer</city>
        <zip>76550</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Husseren Wesserling</city>
        <zip>68470</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kembs</city>
        <zip>68680</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Barre En Ouche</city>
        <zip>27330</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Verdière</city>
        <zip>83560</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Labarth-Sur-Leze</city>
        <zip>31860</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Labarthe-Sur-Leze</city>
        <zip>31860</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Grau Du Roi</city>
        <zip>30240</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Lherm 31600</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Perray En Yvelines</city>
        <zip>78610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lezignan-Corbières</city>
        <zip>11200</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maintenon</city>
        <zip>28130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13001</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13011</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13013</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13014</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13016</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Masevaux</city>
        <zip>68290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maubeuge</city>
        <zip>59600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Monfort sur Risle</city>
        <zip>27290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mulhouse</city>
        <zip>68100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muret</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nassandres</city>
        <zip>27550</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nevers cedex</city>
        <zip>58033</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nogent le Phaye</city>
        <zip>28630</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orbec</city>
        <zip>14290</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75730</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pierres</city>
        <zip>28130</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pinsaguel</city>
        <zip>31120</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roux Mesnil Bouteille</city>
        <zip>76370</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rugles</city>
        <zip>27250</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Leger sur Yvelines</city>
        <zip>78610</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint-Eulalie Badens</city>
        <zip>11800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seysses</city>
        <zip>31600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thann</city>
        <zip>68800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thiberville</city>
        <zip>27230</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31400</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toulouse</city>
        <zip>31500</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trebbes</city>
        <zip>01800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trebes</city>
        <zip>11800</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valenciennes</city>
        <zip>59322</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vogelsheim</city>
        <zip>68600</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Voves</city>
        <zip>28150</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wittenheim</city>
        <zip>68270</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Heidelberg</city>
        <state>Baden-Wuerttemberg</state>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sinsheim</city>
        <state>Baden-Wuerttemberg</state>
        <zip>74889</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stuttgart</city>
        <state>Baden-Wuerttemberg</state>
        <zip>70197</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kronach</city>
        <state>Bayern</state>
        <zip>96317</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wuerzburg</city>
        <state>Bayern</state>
        <zip>97070</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kronberg</city>
        <state>Hessen</state>
        <zip>61476</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ober-Moerlen</city>
        <state>Hessen</state>
        <zip>61239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Offenbach</city>
        <state>Hessen</state>
        <zip>63071</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wetzlar</city>
        <state>Hessen</state>
        <zip>35578</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bad Lauterberg</city>
        <state>Niedersachsen</state>
        <zip>37431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Beckum</city>
        <state>Nordrhein-Westfalen</state>
        <zip>59269</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Menden</city>
        <state>Nordrhein-Westfalen</state>
        <zip>58706</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gau-Algesheim</city>
        <state>Rheinland-Pfalz</state>
        <zip>55435</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kallstadt</city>
        <state>Rheinland-Pfalz</state>
        <zip>67169</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lambrecht</city>
        <state>Rheinland-Pfalz</state>
        <zip>67466</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rhaunen</city>
        <state>Rheinland-Pfalz</state>
        <zip>55624</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Speyer</city>
        <state>Rheinland-Pfalz</state>
        <zip>67346</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Friedrichsthal</city>
        <state>Saarland</state>
        <zip>66299</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Burgstaedt</city>
        <state>Sachsen</state>
        <zip>09217</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chemnitz</city>
        <state>Sachsen</state>
        <zip>09130</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leipzig</city>
        <state>Sachsen</state>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Suhl</city>
        <state>Thueringen</state>
        <zip>98529</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20249</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>115 27</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11521</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>11527</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Athens</city>
        <zip>18537</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Haidari, Athens</city>
        <zip>12462</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ioannina</city>
        <zip>45001</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Maroussi</city>
        <zip>15123</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Patra</city>
        <zip>26335</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Patra</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Piraeus-Athens</city>
        <zip>18454</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Piraeus-Athens</city>
        <zip>18536</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessalonikis</city>
        <zip>57010</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>564 29</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1062</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1083</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1096</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1097</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1115</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1125</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Budapest</city>
        <zip>1145</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Debrecen</city>
        <zip>4043</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eger</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyor</city>
        <zip>9024</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gyula</city>
        <zip>5701</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kurtag99</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nyiregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Patkaj98</city>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Siofok</city>
        <zip>8601</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szentes</city>
        <zip>6600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Szombathely</city>
        <zip>9700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zalaegerszeg</city>
        <zip>8900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reggio Calabria</city>
        <state>Calabria</state>
        <zip>89100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Napoli</city>
        <state>Campania</state>
        <zip>80136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nocera Inferiore (SA)</city>
        <state>Campania</state>
        <zip>84014</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Salerno</city>
        <state>Campania</state>
        <zip>84100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bologna</city>
        <state>Emilia-Romagna</state>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rimini</city>
        <state>Emilia-Romagna</state>
        <zip>47900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00155</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Milano</city>
        <state>Lombardia</state>
        <zip>20162</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Donato (MI)</city>
        <state>Lombardia</state>
        <zip>20097</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Treviglio (BG)</city>
        <state>Lombardia</state>
        <zip>13115</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Campobasso</city>
        <state>Molise</state>
        <zip>86100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10122</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cagliari</city>
        <state>Sardegna</state>
        <zip>09127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sassari</city>
        <state>Sardegna</state>
        <zip>07100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palermo</city>
        <state>Sicilia</state>
        <zip>90127</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Pisa</city>
        <state>Toscana</state>
        <zip>56126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bari</city>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Parma</city>
        <zip>43100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Jekabpils</city>
        <zip>LV 5201</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lagzdi60</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Limbazi</city>
        <zip>LV 4001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ogre</city>
        <zip>LV 5001</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>1006</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1011</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV 1057</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Riga</city>
        <zip>LV1002</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sturii59</city>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tukums</city>
        <zip>LV 3100</zip>
        <country>Latvia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-47144</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-49476</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-50009</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kaunas</city>
        <zip>LT-51270</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Klaipeda</city>
        <zip>92304</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT 08661</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-04318</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vilnius</city>
        <zip>LT-10103</zip>
        <country>Lithuania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Geleen</city>
        <zip>6160 BB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Groningen</city>
        <zip>9711 SG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hengelo</city>
        <zip>7555 DL</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hoogvliet</city>
        <zip>3192 JN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kerkrade</city>
        <zip>6461 XP</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Landgraaf</city>
        <zip>6373 JS</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Musselkanaal</city>
        <zip>9581 AD</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nijmegen</city>
        <zip>6525 EC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oude Pekela</city>
        <zip>9665 AR</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ridderkerk</city>
        <zip>2985 BV</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rijswijk</city>
        <zip>2281 AK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roosendaal</city>
        <zip>4701 LJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3021 HC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3082 KC</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Willebrord</city>
        <zip>4711 EG</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zoetermeer</city>
        <zip>2724 EK</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3331 AE</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zwijndrecht</city>
        <zip>3334 XA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Christchurch</city>
        <zip>8011</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dunedin</city>
        <zip>9016</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hastings</city>
        <zip>Private Bag 9014</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Otahuhu, Auckland</city>
        <zip>2025</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palmerston North</city>
        <zip>4410</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Takapuna, Auckland</city>
        <zip>0620</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Tauranga</city>
        <zip>3112</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wellington</city>
        <zip>6002</zip>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bialystok</city>
        <zip>15-276</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85 822</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gdansk</city>
        <zip>80 211</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Grudziadz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31 261</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krakow</city>
        <zip>31 501</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lodz</city>
        <zip>90 030</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>02 081</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-718</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Olsztyn</city>
        <zip>10 461</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>60-834</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Poznan</city>
        <zip>61 696</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01 887</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-337</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02 507</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-042</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wroclaw</city>
        <zip>50-127</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucharest</city>
        <zip>020475</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>011234</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bucuresti</city>
        <zip>022448</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cluj-Napoca</city>
        <zip>400006</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Craiova</city>
        <zip>2000642</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Iasi</city>
        <zip>700111</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Timisoara</city>
        <zip>293406</zip>
        <country>Romania</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>115 280</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>117049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>125367</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>195257</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Banska Bystrica</city>
        <zip>975 17</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>811 08</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>813 69</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82102</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bratislava</city>
        <zip>82108</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>040 11</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kosice</city>
        <zip>041 90</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kysucke Nove Mesto</city>
        <zip>024 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lubochna</city>
        <zip>034 91</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lucenec</city>
        <zip>984 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Presov</city>
        <zip>08001</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Prievidza</city>
        <zip>97201</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sahy</city>
        <zip>936 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Samorin</city>
        <zip>931 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trencin</city>
        <zip>911 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Zilina</city>
        <zip>010 01</zip>
        <country>Slovakia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08911</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Benidorm</city>
        <zip>03500</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bilbao</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Caceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cadiz</city>
        <zip>11009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18012</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Palma de Mallorca</city>
        <zip>7014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Reus</city>
        <zip>43201</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Santander</city>
        <zip>38008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vazquc56</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vizcaya</city>
        <zip>48910</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vizcaya</city>
        <zip>48920</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Eksjö</city>
        <zip>SE-575 81</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-413 45</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-416 65</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Göteborg</city>
        <zip>SE-417 17</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Helsingborg</city>
        <zip>SE-254 37</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kristianstad</city>
        <zip>SE-291 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kungälv</city>
        <zip>SE-442 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Köping</city>
        <zip>SE-73181</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköpiing</city>
        <zip>SE-582 25</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linköping</city>
        <zip>SE-582 46</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lund</city>
        <zip>SE-221 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mora</city>
        <zip>SE-792 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nacka</city>
        <zip>SE-131 83</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Norrköping</city>
        <zip>SE-602 20</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Oskarshamn</city>
        <zip>SE-572 28</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Skene</city>
        <zip>SE-511 62</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Stockholm</city>
        <zip>SE-182 88</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uddevalla</city>
        <zip>SE-451 40</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Umeå</city>
        <zip>SE-901 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uppsala</city>
        <zip>SE-751 25</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vadstena</city>
        <zip>SE-592 32</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dnepropetrovsk</city>
        <zip>49044</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kharkiv</city>
        <zip>61002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>02175</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kiev</city>
        <zip>04114</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kyiv</city>
        <zip>01004</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lvov</city>
        <zip>79010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vinnitsa</city>
        <zip>21010</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cambridge</city>
        <state>Cambridgeshire</state>
        <zip>CB2 2QQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fowley</city>
        <state>Cornwall</state>
        <zip>PL23 1DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S40 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <state>Derbyshire</state>
        <zip>S44 6DE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Airdrie</city>
        <state>Lanarkshire</state>
        <zip>ML6 0JS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <state>Lanarkshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Lanarkshire</state>
        <zip>ML3 0DR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Motherwell</city>
        <state>Lanarkshire</state>
        <zip>ML1 3JX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leicester</city>
        <state>Leicestershire</state>
        <zip>LE1 5WW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northampton</city>
        <state>Northamptonshire</state>
        <zip>NN1 5BD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Northampton</city>
        <state>Northamptonshire</state>
        <zip>NN5 7AQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Linwood</city>
        <state>Renfrewshire</state>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paisley</city>
        <state>Renfrewshire</state>
        <zip>PA1 1UB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frome</city>
        <state>Somerset</state>
        <zip>BA11 1EZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glastonbury</city>
        <state>Somerset</state>
        <zip>BA6 9LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rugby</city>
        <state>Warwickshire</state>
        <zip>CV21 3SP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rugby</city>
        <state>Warwickshire</state>
        <zip>CV22 5PX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Corsham</city>
        <state>Wiltshire</state>
        <zip>SN13 9DL</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <state>Wiltshire</state>
        <zip>BA14 8QA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Trowbridge</city>
        <state>Wiltshire</state>
        <zip>BA14 9AR</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Westbury</city>
        <state>Wiltshire</state>
        <zip>BA13 3JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Airdrie</city>
        <zip>ML6 0JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Airdrie</city>
        <zip>ML6 0JU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ashford</city>
        <zip>TW15 2TU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bath</city>
        <zip>BA2 3HT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chesterfield</city>
        <zip>S40 1LE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Chippenham</city>
        <zip>SN15 2SB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Coatbridge</city>
        <zip>ML5 3AP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Colney</city>
        <zip>NR4 7UY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cumbernauld</city>
        <zip>G67 3BE</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dronfield</city>
        <zip>S18 1RU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dumbarton</city>
        <zip>G82 1PW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>East Kilbride</city>
        <zip>G75 8RG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Falmouth</city>
        <zip>TR11 2LH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garston, Watford</city>
        <zip>WD2 6EB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Gateshead</city>
        <zip>NE9 6SX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G5 OPQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Glasgow</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <zip>ML3 8AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Harrow</city>
        <zip>HA3 7LT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Kirkintilloch</city>
        <zip>G66 1JB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Leigh on Sea</city>
        <zip>SS9 2SQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Motherwell</city>
        <zip>ML1 2PS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newcastle upon Tyne</city>
        <zip>NE1 4LP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Newport</city>
        <zip>PO30 5TG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nottingham</city>
        <zip>NG5 1PB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Old Whittington, Chesterfield</city>
        <zip>S41 9JZ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paisley</city>
        <zip>PA3 2DY</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Penzance</city>
        <zip>TR18 4JH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rubery, Birmingham</city>
        <zip>B45 9JT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7QB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sheffield</city>
        <zip>S5 7TW</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thornhill, Cardiff</city>
        <zip>CF14 9BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Thornhill</city>
        <zip>DG3 5AA</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Uddingston</city>
        <zip>G71 5SU</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Weston Super Mare</city>
        <zip>BS23 4BP</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Wishaw</city>
        <zip>ML2 7BQ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Woking</city>
        <zip>GU21 1TD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Worle, Weston-Super-Mare</city>
        <zip>BS22 6AJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Bulgaria</country>
    <country>Croatia</country>
    <country>Czech Republic</country>
    <country>Denmark</country>
    <country>Estonia</country>
    <country>Finland</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Italy</country>
    <country>Latvia</country>
    <country>Lithuania</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Romania</country>
    <country>Russian Federation</country>
    <country>Slovakia</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>Ukraine</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.clinicalstudydatarequest.com</url>
    <description>Researchers can use this site to request access to anonymised patient level data and/or supporting documents from clinical studies to conduct further research.</description>
  </link>
  <reference>
    <citation>Home PD, Jones NP, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Komajda M, Curtis P; RECORD Study Group. Rosiglitazone RECORD study: glucose control outcomes at 18 months. Diabet Med. 2007 Jun;24(6):626-34.</citation>
    <PMID>17517066</PMID>
  </reference>
  <reference>
    <citation>Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Dargie H, Komajda M, Gubb J, Biswas N, Jones NP. Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycaemia in Diabetes (RECORD): study design and protocol. Diabetologia. 2005 Sep;48(9):1726-35. Epub 2005 Jul 16.</citation>
    <PMID>16025252</PMID>
  </reference>
  <reference>
    <citation>Home PD, Pocock SJ, Beck-Nielsen H, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Group. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. N Engl J Med. 2007 Jul 5;357(1):28-38. Epub 2007 Jun 5.</citation>
    <PMID>17551159</PMID>
  </reference>
  <reference>
    <citation>Home PD, Pocock SJ, Beck-Nielsen H, Curtis PS, Gomis R, Hanefeld M, Jones NP, Komajda M, McMurray JJ; RECORD Study Team. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. Lancet. 2009 Jun 20;373(9681):2125-35. doi: 10.1016/S0140-6736(09)60953-3. Epub 2009 Jun 6.</citation>
    <PMID>19501900</PMID>
  </reference>
  <reference>
    <citation>Komajda M, Curtis P, Hanefeld M, Beck-Nielsen H, Pocock SJ, Zambanini A, Jones NP, Gomis R, Home PD; RECORD Study Group. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). Cardiovasc Diabetol. 2008 Apr 24;7:10. doi: 10.1186/1475-2840-7-10.</citation>
    <PMID>18435852</PMID>
  </reference>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 21, 2006</study_first_submitted>
  <study_first_submitted_qc>September 21, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2006</study_first_posted>
  <results_first_submitted>August 24, 2009</results_first_submitted>
  <results_first_submitted_qc>October 7, 2009</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 13, 2009</results_first_posted>
  <last_update_submitted>March 21, 2017</last_update_submitted>
  <last_update_submitted_qc>March 21, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>CV outcomes</keyword>
  <keyword>rosiglitazone</keyword>
  <keyword>Type II diabetes</keyword>
  <keyword>sulfonylurea</keyword>
  <keyword>RECORD</keyword>
  <keyword>metformin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rosiglitazone</mesh_term>
    <mesh_term>Metformin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.</ipd_description>
  </patient_data>
  <study_docs>
    <study_doc>
      <doc_id>BRL-049653/231</doc_id>
      <doc_type>Informed Consent Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>BRL-049653/231</doc_id>
      <doc_type>Statistical Analysis Plan</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>BRL-049653/231</doc_id>
      <doc_type>Annotated Case Report Form</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>BRL-049653/231</doc_id>
      <doc_type>Study Protocol</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>BRL-049653/231</doc_id>
      <doc_type>Clinical Study Report</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>BRL-049653/231</doc_id>
      <doc_type>Individual Participant Data Set</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
    <study_doc>
      <doc_id>BRL-049653/231</doc_id>
      <doc_type>Dataset Specification</doc_type>
      <doc_url>https://www.clinicalstudydatarequest.com</doc_url>
      <doc_comment>For additional information about this study please refer to the GSK Clinical Study Register</doc_comment>
    </study_doc>
  </study_docs>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The RECORD study ran from April 2001 through December 2008. Results are presented in the non-re-adjudicated outcome measures (OMs). An independent patient-level re-adjudication of mortality, non-fatal myocardial infarction, and non-fatal stroke began on January 2011 and ran through March 2012. The results are presented in the re-adjudicated OMs.</recruitment_details>
      <pre_assignment_details>The RECORD observational follow-up (OFU) started at the end of the RECORD study and ran through December 2012. OFU was designed to collect cancer and bone fracture data. Participants were not provided with study medication in the OFU. Data are presented for the entire study (RECORD + OBF) and for OFU alone in the observational OMs.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>RSG in Addition to Background MET</title>
          <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="P2">
          <title>SU in Addition to Background MET</title>
          <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="P3">
          <title>RSG in Addition to Background SU</title>
          <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="P4">
          <title>MET in Addition to Background SU</title>
          <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="P5">
          <title>Combined RSG: Observational Follow-up</title>
          <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
        </group>
        <group group_id="P6">
          <title>Combined MET/SU: Observational Follow-up</title>
          <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Main Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1117"/>
                <participants group_id="P2" count="1105"/>
                <participants group_id="P3" count="1103"/>
                <participants group_id="P4" count="1122"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="939"/>
                <participants group_id="P2" count="906"/>
                <participants group_id="P3" count="896"/>
                <participants group_id="P4" count="892"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="178"/>
                <participants group_id="P2" count="199"/>
                <participants group_id="P3" count="207"/>
                <participants group_id="P4" count="230"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="57"/>
                <participants group_id="P2" count="67"/>
                <participants group_id="P3" count="54"/>
                <participants group_id="P4" count="72"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="8"/>
                <participants group_id="P3" count="10"/>
                <participants group_id="P4" count="11"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="29"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="26"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="46"/>
                <participants group_id="P2" count="56"/>
                <participants group_id="P3" count="72"/>
                <participants group_id="P4" count="70"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Moved to survival status follow-up only</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="36"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant moved</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor compliance</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Prohibited glucose lowering medication</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site closed</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entry criteria violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant did not take study drug</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant completed study at visit 27</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Personal reasons</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Risk of heart failure</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Investigator refused to log temperature</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Reason unspecified</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Observational Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1280">665 from “RSG in Addition to Background MET” arm; 615 from “RGS in Addition to Background SU” arm.</participants>
                <participants group_id="P6" count="1250">647 from “SU in Addition to Background MET” arm; 603 from “MET in Addition to Background SU” arm.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1131"/>
                <participants group_id="P6" count="1102"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="149"/>
                <participants group_id="P6" count="148"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="78"/>
                <participants group_id="P6" count="70"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="25"/>
                <participants group_id="P6" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="12"/>
                <participants group_id="P6" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Entered into Another Clinical Trial</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="18"/>
                <participants group_id="P6" count="22"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="8"/>
                <participants group_id="P6" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Site Closed Early</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="6"/>
                <participants group_id="P6" count="7"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant Moved</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Unknown; Reason Not Provided</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>RSG in Addition to Background MET</title>
          <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="B2">
          <title>SU in Addition to Background MET</title>
          <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="B3">
          <title>RSG in Addition to Background SU</title>
          <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="B4">
          <title>MET in Addition to Background SU</title>
          <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1117"/>
            <count group_id="B2" value="1105"/>
            <count group_id="B3" value="1103"/>
            <count group_id="B4" value="1122"/>
            <count group_id="B5" value="4447"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57.0" spread="8.02"/>
                    <measurement group_id="B2" value="57.2" spread="8.14"/>
                    <measurement group_id="B3" value="59.8" spread="8.26"/>
                    <measurement group_id="B4" value="59.7" spread="8.23"/>
                    <measurement group_id="B5" value="58.4" spread="8.27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="516"/>
                    <measurement group_id="B2" value="521"/>
                    <measurement group_id="B3" value="562"/>
                    <measurement group_id="B4" value="554"/>
                    <measurement group_id="B5" value="2153"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="601"/>
                    <measurement group_id="B2" value="584"/>
                    <measurement group_id="B3" value="541"/>
                    <measurement group_id="B4" value="568"/>
                    <measurement group_id="B5" value="2294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1105"/>
                    <measurement group_id="B2" value="1087"/>
                    <measurement group_id="B3" value="1095"/>
                    <measurement group_id="B4" value="1112"/>
                    <measurement group_id="B5" value="4399"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oriental</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="7"/>
                    <measurement group_id="B5" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Aboriginal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Egyptian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gipsy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Indian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Maori</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Middle East Hible</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Polynesian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sri Lankan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Tahitian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events</title>
        <description>The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Death/Cardiovascular Hospitalisation Events</title>
          <description>The number of participants with cardiovascular death events (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation events (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) was recorded.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="321"/>
                    <measurement group_id="O2" value="323"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority margin of 1.2 for the upper limit of the 95 percent confidence interval in time to event analysis comparing RSG to MET/SU stratified by background medication</non_inferiority_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.85</ci_lower_limit>
            <ci_upper_limit>1.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Cardiovascular Events and All-cause Deaths</title>
        <description>Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Cardiovascular Events and All-cause Deaths</title>
          <description>Composites of participants with first cardiovascular (CV) hospitalisations and CV death or all-cause death and individual first events of acute myocardial infarction (MI) , stroke, congestive heart failure (CHF), CV death, and all-cause death.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CV death, acute MI, stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CV death, acute MI, stroke, unstable angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="171"/>
                    <measurement group_id="O2" value="184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CV death, acute MI, stroke, unstable angina, CHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="204"/>
                    <measurement group_id="O2" value="206"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>All-cause death,acuteMI,stroke,unstable angina,CHF</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251"/>
                    <measurement group_id="O2" value="268"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute MI (fatal or non-fatal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stroke (fatal or non-fatal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CHF (fatal or non-fatal)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death from CV causes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (all cause) during CV follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="111"/>
                    <measurement group_id="O2" value="139"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death (all-cause) including survival status</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="136"/>
                    <measurement group_id="O2" value="157"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths</title>
        <description>The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Total Number of Cardiovascular Hospitalisations and Cardiovascular Deaths</title>
          <description>The total number of events for individual components of cardiovascular (CV) hospitalisations and cardiovascular deaths were recorded. MI, myocardial infarction.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>Number of events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CV deaths</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death due to acute MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death due to heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sudden death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death due to acute vascular events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other CV mortality</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death of presumed CV cause</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiovascular hospitalisation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="483"/>
                    <measurement group_id="O2" value="490"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation for acute MI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation for unstable angina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation for congestive heart failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69"/>
                    <measurement group_id="O2" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation for stroke</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation for transient ischaemic attack</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation for invasive CV procedure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hospitalisation for amputation of extremities</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other CV hospitalisations</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="154"/>
                    <measurement group_id="O2" value="153"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum</title>
        <description>Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With First Cardiovascular Hospitalisations/Cardiovascular Deaths by Stratum</title>
          <description>Participants with first cardiovascular death (death due to cardiovascular causes or deaths with insufficient information to rule out a cardiovascular cause) and cardiovascular hospitalisation (hospitalisation for a cardiovascular event, excluding planned admissions not associated with a worsening of the disease/condition of the participant) were recorded by study stratum.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>partcipants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1105"/>
                <count group_id="O3" value="1103"/>
                <count group_id="O4" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="158"/>
                    <measurement group_id="O2" value="154"/>
                    <measurement group_id="O3" value="163"/>
                    <measurement group_id="O4" value="169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With CV/Microvascular Events</title>
        <description>The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With CV/Microvascular Events</title>
          <description>The number of participants with first cardiovascular or microvascular events (renal, foot, eye) were recorded.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with a CV/Microvascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="363"/>
                    <measurement group_id="O2" value="385"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with any microvascular event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with any eye event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with any foot event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with any renal event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Glycaemic Failure Events</title>
        <description>Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started.</description>
        <time_frame>Baseline through to end of randomised dual therapy</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Glycaemic Failure Events</title>
          <description>Failure of glycaemic control was defined as two consecutive HbA1c values of ≥8.5 percent, or HbA1c ≥8.5percent at a single visit, after which the subject was either moved to the post-randomised treatment phase or triple therapy was started.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1105"/>
                <count group_id="O3" value="1103"/>
                <count group_id="O4" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281"/>
                    <measurement group_id="O2" value="451"/>
                    <measurement group_id="O3" value="365"/>
                    <measurement group_id="O4" value="424"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Addition of Third Oral Agent/Switch to Insulin</title>
        <description>The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Addition of Third Oral Agent/Switch to Insulin</title>
          <description>The number of participants with addition of a third oral agent or switch to insulin from randomised dual combination treatment were recorded.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1105"/>
                <count group_id="O3" value="1103"/>
                <count group_id="O4" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with an event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="295"/>
                    <measurement group_id="O2" value="183"/>
                    <measurement group_id="O3" value="344"/>
                    <measurement group_id="O4" value="171"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Event - Triple Therapy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="257"/>
                    <measurement group_id="O2" value="7"/>
                    <measurement group_id="O3" value="296"/>
                    <measurement group_id="O4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>First Event - Insulin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="176"/>
                    <measurement group_id="O3" value="49"/>
                    <measurement group_id="O4" value="165"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>The Number of Participants Starting Insulin at Any Time During the Study</title>
        <description>The number of participants starting insulin at any time during the study was recorded.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>The Number of Participants Starting Insulin at Any Time During the Study</title>
          <description>The number of participants starting insulin at any time during the study was recorded.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1105"/>
                <count group_id="O3" value="1103"/>
                <count group_id="O4" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="126"/>
                    <measurement group_id="O2" value="276"/>
                    <measurement group_id="O3" value="168"/>
                    <measurement group_id="O4" value="259"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Change From Baseline in HbA1c at Month 60</title>
        <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value.</description>
        <time_frame>Baseline and Month 60 of randomised dual therapy treatment period</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Change From Baseline in HbA1c at Month 60</title>
          <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in HbA1c was calculated as the value at Month 60 minus the Baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>Percent</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1096"/>
                <count group_id="O2" value="1079"/>
                <count group_id="O3" value="1073"/>
                <count group_id="O4" value="1079"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.14" spread="0.035"/>
                    <measurement group_id="O2" value="0.17" spread="0.042"/>
                    <measurement group_id="O3" value="-0.24" spread="0.039"/>
                    <measurement group_id="O4" value="-0.10" spread="0.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60</title>
        <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value.</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Change From Baseline in Fasting Plasma Glucose at Month 60</title>
          <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in fasting plasma glucose was calculated as the value at Month 60 minus the Baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>mmol/L (millimoles/Liter)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1095"/>
                <count group_id="O2" value="1078"/>
                <count group_id="O3" value="1074"/>
                <count group_id="O4" value="1079"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.38" spread="0.073"/>
                    <measurement group_id="O2" value="-0.29" spread="0.090"/>
                    <measurement group_id="O3" value="-2.00" spread="0.085"/>
                    <measurement group_id="O4" value="-0.94" spread="0.094"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60</title>
        <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value.</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Mean Change From Baseline in Insulin and Pro-insulin at Month 60</title>
          <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in insulin and pro-insulin was calculated as the value at Month 60 minus the Baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>picamoles/liter (pmol/L)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="931"/>
                <count group_id="O2" value="982"/>
                <count group_id="O3" value="882"/>
                <count group_id="O4" value="940"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Insulin, Adjusted Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-18.6" spread="1.01"/>
                    <measurement group_id="O2" value="3.7" spread="1.77"/>
                    <measurement group_id="O3" value="-16.9" spread="1.65"/>
                    <measurement group_id="O4" value="-12.1" spread="1.91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pro-insulin, Adjusted Change from Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.4" spread="0.26"/>
                    <measurement group_id="O2" value="4.2" spread="0.43"/>
                    <measurement group_id="O3" value="-3.2" spread="0.48"/>
                    <measurement group_id="O4" value="-3.0" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60</title>
        <description>Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L)</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of HbA1c and Fasting Plasma Glucose (FPG) Responders at Month 60</title>
          <description>Number of responders, i.e., participants meeting glycaemic targets (HbA1c less than or equal to 7 percent, FPG less than or equal to 7 mmol/L)</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1105"/>
                <count group_id="O3" value="1103"/>
                <count group_id="O4" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>HbA1c Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="265"/>
                    <measurement group_id="O2" value="208"/>
                    <measurement group_id="O3" value="235"/>
                    <measurement group_id="O4" value="180"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>FPG Responders</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="300"/>
                    <measurement group_id="O2" value="180"/>
                    <measurement group_id="O3" value="257"/>
                    <measurement group_id="O4" value="154"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) Homeostasis Model Assessment (HOMA) Beta Cell Function and Insulin Sensitivity at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in HOMA beta-cell function and insulin sensitivity was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="926"/>
                <count group_id="O2" value="977"/>
                <count group_id="O3" value="878"/>
                <count group_id="O4" value="933"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Beta cell function</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.54" lower_limit="16.52" upper_limit="24.70"/>
                    <measurement group_id="O2" value="19.28" lower_limit="14.66" upper_limit="24.09"/>
                    <measurement group_id="O3" value="32.35" lower_limit="26.55" upper_limit="38.41"/>
                    <measurement group_id="O4" value="12.43" lower_limit="7.42" upper_limit="17.67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Insulin sensitivity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42.57" lower_limit="37.57" upper_limit="47.76"/>
                    <measurement group_id="O2" value="-3.45" lower_limit="-7.21" upper_limit="0.47"/>
                    <measurement group_id="O3" value="42.07" lower_limit="36.39" upper_limit="47.98"/>
                    <measurement group_id="O4" value="23.90" lower_limit="19.36" upper_limit="28.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC), Low-density Lipoprotein (LDL) Cholesterol, High-density Lipoprotein (HDL) Cholesterol, Triglycerides, and Free Fatty Acids (FFAs) at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC, LDL cholesterol, HDL cholesterol, triglycerides, and FFAs was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1105"/>
                <count group_id="O3" value="1103"/>
                <count group_id="O4" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-5.49" lower_limit="-6.99" upper_limit="-3.96"/>
                    <measurement group_id="O2" value="-9.09" lower_limit="-10.33" upper_limit="-7.84"/>
                    <measurement group_id="O3" value="-2.91" lower_limit="-4.62" upper_limit="-1.17"/>
                    <measurement group_id="O4" value="-9.68" lower_limit="-11.03" upper_limit="-8.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>HDL-cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.95" lower_limit="8.44" upper_limit="11.49"/>
                    <measurement group_id="O2" value="2.57" lower_limit="1.46" upper_limit="3.68"/>
                    <measurement group_id="O3" value="7.73" lower_limit="6.18" upper_limit="9.30"/>
                    <measurement group_id="O4" value="6.14" lower_limit="4.88" upper_limit="7.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL-cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-12.70" lower_limit="-15.03" upper_limit="-10.30"/>
                    <measurement group_id="O2" value="-17.68" lower_limit="-19.70" upper_limit="-15.61"/>
                    <measurement group_id="O3" value="-8.99" lower_limit="-11.42" upper_limit="-6.49"/>
                    <measurement group_id="O4" value="-17.80" lower_limit="-19.93" upper_limit="-15.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-7.97" lower_limit="-10.72" upper_limit="-5.15"/>
                    <measurement group_id="O2" value="-1.95" lower_limit="-4.73" upper_limit="0.91"/>
                    <measurement group_id="O3" value="-2.68" lower_limit="-5.69" upper_limit="0.43"/>
                    <measurement group_id="O4" value="-2.50" lower_limit="-5.21" upper_limit="0.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Free fatty acids</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-16.46" lower_limit="-19.13" upper_limit="-13.71"/>
                    <measurement group_id="O2" value="2.79" lower_limit="-0.23" upper_limit="5.91"/>
                    <measurement group_id="O3" value="-11.58" lower_limit="-14.65" upper_limit="-8.41"/>
                    <measurement group_id="O4" value="4.47" lower_limit="1.23" upper_limit="7.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Total Cholesterol (TC):High-density Lipoprotein (HDL) Cholesterol and Low-density Lipoprotein (LDL) Cholesterol:HDL Cholesterol Ratios at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in TC:HDL cholesterol and LDL cholesterol:HDL cholesterol was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1117"/>
                <count group_id="O2" value="1105"/>
                <count group_id="O3" value="1103"/>
                <count group_id="O4" value="1122"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Total Cholesterol: HDL Cholesterol Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.20" lower_limit="-15.98" upper_limit="-12.39"/>
                    <measurement group_id="O2" value="-11.33" lower_limit="-12.82" upper_limit="-9.81"/>
                    <measurement group_id="O3" value="-9.93" lower_limit="-11.83" upper_limit="-7.98"/>
                    <measurement group_id="O4" value="-15.01" lower_limit="-16.44" upper_limit="-13.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL Cholesterol: HDL-Cholesterol Ratio</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-20.89" lower_limit="-23.24" upper_limit="-18.46"/>
                    <measurement group_id="O2" value="-20.04" lower_limit="-22.16" upper_limit="-17.87"/>
                    <measurement group_id="O3" value="-15.85" lower_limit="-18.26" upper_limit="-13.37"/>
                    <measurement group_id="O4" value="-22.53" lower_limit="-24.63" upper_limit="-20.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment period</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Apolipoprotein B (Apo-B) at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in Apo-B was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="949"/>
                <count group_id="O2" value="1007"/>
                <count group_id="O3" value="906"/>
                <count group_id="O4" value="970"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-13.77" lower_limit="-15.45" upper_limit="-12.05"/>
                    <measurement group_id="O2" value="-11.63" lower_limit="-13.10" upper_limit="-10.14"/>
                    <measurement group_id="O3" value="-9.68" lower_limit="-11.55" upper_limit="-7.77"/>
                    <measurement group_id="O4" value="-12.09" lower_limit="-13.67" upper_limit="-10.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Urinary Albumin Creatinine Ratio at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in urinary albumin creatinine ratio was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="899"/>
                <count group_id="O2" value="921"/>
                <count group_id="O3" value="891"/>
                <count group_id="O4" value="901"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8.31" lower_limit="-0.70" upper_limit="18.14"/>
                    <measurement group_id="O2" value="15.17" lower_limit="6.73" upper_limit="24.28"/>
                    <measurement group_id="O3" value="-3.43" lower_limit="-11.91" upper_limit="5.87"/>
                    <measurement group_id="O4" value="11.91" lower_limit="3.10" upper_limit="21.46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Change From Baseline in Body Weight at Month 60</title>
        <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value.</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive RSG, in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Change From Baseline in Body Weight at Month 60</title>
          <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in body weight was calculated as the value at Month 60 minus the Baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1096"/>
                <count group_id="O2" value="1079"/>
                <count group_id="O3" value="1073"/>
                <count group_id="O4" value="1079"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.93" spread="0.263"/>
                    <measurement group_id="O2" value="-0.54" spread="0.192"/>
                    <measurement group_id="O3" value="4.72" spread="0.235"/>
                    <measurement group_id="O4" value="-2.16" spread="0.179"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60</title>
        <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value.</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive RSG, in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or miconizied equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Change From Baseline in Alanine Aminotransferase at Month 60</title>
          <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in alanine aminotransferase was calculated as the value at Month 60 minus the Baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>U/L (Units/Liter)</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1094"/>
                <count group_id="O2" value="1077"/>
                <count group_id="O3" value="1073"/>
                <count group_id="O4" value="1078"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-37.43" lower_limit="-39.22" upper_limit="-35.59"/>
                    <measurement group_id="O2" value="-21.73" lower_limit="-23.90" upper_limit="-19.50"/>
                    <measurement group_id="O3" value="-30.17" lower_limit="-31.98" upper_limit="-28.31"/>
                    <measurement group_id="O4" value="-24.00" lower_limit="-26.21" upper_limit="-21.73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Change From Baseline in Waist Circumference at Month 60</title>
        <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value.</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive RSG, in addition to MET. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15mg per day or miconizied equivalent of 10.5mg per day; gliclazide 240mg per day and glimepiride 4mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Change From Baseline in Waist Circumference at Month 60</title>
          <description>Model adjusted (adjusted for any imbalances in the baseline values between within stratum treatment groups) change from baseline in waist circumference was calculated as the value at Month 60 minus the Baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>cm (centimeters)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="972"/>
                <count group_id="O2" value="1032"/>
                <count group_id="O3" value="926"/>
                <count group_id="O4" value="994"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.70" spread="0.266"/>
                    <measurement group_id="O2" value="0.65" spread="0.214"/>
                    <measurement group_id="O3" value="3.00" spread="0.263"/>
                    <measurement group_id="O4" value="-0.60" spread="0.215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60</title>
        <description>Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value.</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive RSG, in addition to MET. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15mg per day or miconizied equivalent of 10.5mg per day; gliclazide 240mg per day and glimepiride 4mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Change From Baseline in Systolic Blood Pressure (SBP) and Diastolic Blood Pressure (DBP) at Month 60</title>
          <description>Model adjusted (adjusted for any imbalances in the baseline values between within treatment groups) change from baseline in SBP and DBP was calculated as the value at Month 60 minus the Baseline value.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>mmHg (millimeters of mercury)</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1096"/>
                <count group_id="O2" value="1079"/>
                <count group_id="O3" value="1074"/>
                <count group_id="O4" value="1079"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>SBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.9" spread="0.54"/>
                    <measurement group_id="O2" value="-2.2" spread="0.52"/>
                    <measurement group_id="O3" value="-2.3" spread="0.52"/>
                    <measurement group_id="O4" value="-0.6" spread="0.53"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>DBP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.6" spread="0.34"/>
                    <measurement group_id="O2" value="-3.4" spread="0.29"/>
                    <measurement group_id="O3" value="-3.6" spread="0.31"/>
                    <measurement group_id="O4" value="-2.3" spread="0.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive RSG, in addition to MET. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15mg per day or miconizied equivalent of 10.5mg per day; gliclazide 240mg per day and glimepiride 4mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for C-Reactive Protein at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in C-Reactive Protein was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="942"/>
                <count group_id="O2" value="987"/>
                <count group_id="O3" value="887"/>
                <count group_id="O4" value="952"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-57.40" lower_limit="-60.41" upper_limit="-54.15"/>
                    <measurement group_id="O2" value="-28.92" lower_limit="-33.71" upper_limit="-23.79"/>
                    <measurement group_id="O3" value="-56.50" lower_limit="-61.56" upper_limit="-55.21"/>
                    <measurement group_id="O4" value="-36.29" lower_limit="-41.03" upper_limit="-31.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive RSG, in addition to MET. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15mg per day or miconizied equivalent of 10.5mg per day; gliclazide 240mg per day and glimepiride 4mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Fibrinogen at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in fibrinogen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="918"/>
                <count group_id="O2" value="987"/>
                <count group_id="O3" value="875"/>
                <count group_id="O4" value="941"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.12" lower_limit="0.54" upper_limit="3.72"/>
                    <measurement group_id="O2" value="5.74" lower_limit="4.22" upper_limit="7.28"/>
                    <measurement group_id="O3" value="-0.23" lower_limit="-1.79" upper_limit="1.35"/>
                    <measurement group_id="O4" value="3.14" lower_limit="1.38" upper_limit="4.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60</title>
        <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
        <time_frame>Baseline to Month 60 of the randomised dual therapy treatment phase</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>RSG in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive RSG, in addition to MET. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O2">
            <title>SU in Addition to Background MET</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15mg per day or miconizied equivalent of 10.5mg per day; gliclazide 240mg per day and glimepiride 4mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O3">
            <title>RSG in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4mg once daily dose and was increased to a maximum dose of 8mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
          <group group_id="O4">
            <title>MET in Addition to Background SU</title>
            <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Model Adjusted Ratio to Baseline (Expressed as a Percentage) for Plasminogen Activator Inhibitor-1 (PAI-1) Antigen at Month 60</title>
          <description>The model adjusted (adjusted for any imbalances in the baseline [BL] values between within stratum treatment groups) ratio to BL in plasminogen activator inhibitor-1 (PAI-1) antigen was calculated as the ratio of the Month 60 value to the BL value and was expressed as percent change from BL. For each treatment group, the model-adjusted mean change from BL at Month 60 was determined on the log scale. This mean was then back transformed to give a geometric mean (GM) of the ratio of the Month 60 value to BL on the original scale. The GM was expressed as a percentage (100*[GM^-1]).</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>percent change</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="931"/>
                <count group_id="O2" value="991"/>
                <count group_id="O3" value="882"/>
                <count group_id="O4" value="939"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.85" lower_limit="-14.42" upper_limit="-5.02"/>
                    <measurement group_id="O2" value="15.01" lower_limit="9.77" upper_limit="20.50"/>
                    <measurement group_id="O3" value="-7.79" lower_limit="-12.61" upper_limit="-2.71"/>
                    <measurement group_id="O4" value="-0.64" lower_limit="-5.82" upper_limit="4.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause</title>
        <description>All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants Who Died Due to Any Cause</title>
          <description>All deaths identified during the original record study and discovered after the re-adjudication efforts began were included.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="139"/>
                    <measurement group_id="O2" value="160"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.86</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions</title>
        <description>IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication (IR) Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Original RECORD Endpoint Definitions</title>
          <description>IR was based on original RECORD endpoint definitions. CV death= no unequivocal non-CV cause (sudden death, death from acute vascular events, heart failure, acute MI, other CV causes, and deaths adjudicated as unknown cause). MI event=hospitalization + elevation of specific cardiac biomarkers above the upper limit of normal + cardiac ischemia symptoms/new pathological electrocardiogram findings. Stroke event=hospitalization + rapidly developed clinical signs of focal/global disturbance of cerebral function for more than 24 hours, with no apparent cause other than a vascular origin.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="181"/>
                    <measurement group_id="O2" value="188"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.95</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.78</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions</title>
        <description>Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants With a First Occurrence of a Major Adverse Cardiovascular Event (MACE) Defined as CV (or Unknown) Death, Non-fatal MI, and Non-fatal Stroke Based on Contemporary Endpoint Definitions</title>
          <description>Independent re-adjudication was based on the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions. CV death included death resulting from an acute MI; sudden cardiac death and death due to heart failure, stroke, and to other CV causes. Deaths of unknown cause were counted as CV deaths. MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia. Stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="186"/>
                    <measurement group_id="O2" value="191"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.97</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.79</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions</title>
        <description>The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as &quot;unknown deaths,&quot; but were counted as CV deaths for the analysis of this endpoint.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Original RECORD Endpoint Definitions</title>
          <description>The number of participants with a CV death (or unknown) as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. CV death was defined as any death for which an unequivocal non-CV cause could not be established. CV death included death following heart failure, death following acute myocardial infarction (MI), sudden death, death due to acute vascular events, and other CV causes. Deaths due to unknown causes were classified as &quot;unknown deaths,&quot; but were counted as CV deaths for the analysis of this endpoint.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions</title>
        <description>The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants With a CV (or Unknown) Death, Based on Contemporary Endpoint Definitions</title>
          <description>The number of participants with a CV (or unknown) death as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. CV death included death resulting from an acute myocardial infarction (MI), sudden cardiac death, death due to heart failure, death due to stroke, and death due to other CV causes. Deaths of unknown cause were counted as CV deaths.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="96"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.90</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.68</ci_lower_limit>
            <ci_upper_limit>1.21</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions</title>
        <description>The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme &gt;= 2x the ULN or CK &gt; 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions</title>
          <description>The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. An event of MI was defined as hospitalization plus elevation of cardiac biomarkers troponin (TN) I and/or TNT above the upper limit of normal (ULN) or creatinine kinase (CK) MB (M=muscle type; B=brain type) isoenzyme &gt;= 2x the ULN or CK &gt; 2x the ULN plus typical symptoms of cardiac ischemia or new pathological electrocardiogram findings, or cause of death adjudicated as MI.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.80</ci_lower_limit>
            <ci_upper_limit>1.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions</title>
        <description>The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants With an Event of Myocardial Infarction (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions</title>
          <description>The number of participants with an MI (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of MI was defined as evidence of myocardial necrosis in a clinical setting consistent with myocardial ischemia.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.62</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions</title>
        <description>Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants (Par.) With an Event of Stroke (Fatal and Non-fatal), Based on Original RECORD Endpoint Definitions</title>
          <description>Par. with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the original RECORD endpoint definitions was recorded. A stroke event=hospitalization plus rapidly developed clinical signs of focal (or global) disturbance of cerebral function lasting more than 24 hours (unless interrupted by thrombolysis, surgery, or death), with no apparent cause other than a vascular origin, including par. presenting clinical signs/symptoms suggestive of subarachnoid haemorrhage/intracerebral haemorrhage/cerebral ischemic necrosis or cause of death adjudicated as stroke.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="50"/>
                    <measurement group_id="O2" value="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.79</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.54</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions</title>
        <description>The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.</description>
        <time_frame>Baseline through End of Study (up to 7.5 years)</time_frame>
        <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG</title>
            <description>Participants inadequately controlled on background MET or background SU were randomised to receive RSG, in addition to MET or SU. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU</title>
            <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, an SU (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent. Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
          </group>
        </group_list>
        <measure>
          <title>Independent Re-adjudication Outcome: Number of Participants With an Event of Stroke (Fatal and Non-fatal), Based on Contemporary Endpoint Definitions</title>
          <description>The number of participants with a stroke (fatal or non-fatal) event as determined by independent re-adjudication using the Standard Data Collection for Cardiovascular Trials Initiative (draft October 2011) endpoint definitions was recorded. An event of stroke was defined as an acute episode of neurological dysfunction caused by focal or global brain, spinal cord, or retinal vascular injury.</description>
          <population>Intent-to-Treat (ITT) Population: all randomized participants who were treated with at least one dose of study medication</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53"/>
                    <measurement group_id="O2" value="64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.82</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.18</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All neoplasms/cancer (N/C) (benign/malignant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="196"/>
                    <measurement group_id="O2" value="215"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant (Mal.) N/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="179"/>
                    <measurement group_id="O2" value="195"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mal. N/C; excluding non-melanomatous skin cancers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="164"/>
                    <measurement group_id="O2" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Type of Neoplasm/Cancer Event Reported as a Serious Adverse Event (SAE) or Death: Observational Follow-up</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>All neoplasms/cancer (N/C) (benign/malignant)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant (Mal.) N/C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mal. N/C; excluding non-melanomatous skin cancers</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal/vulvar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon/rectal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gall bladder/biliary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal; not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hematologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (non-melanomatous)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (melanomatous)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up</title>
        <description>The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Type of Malignant Neoplasms/Cancer Events Reported as an SAE or Death by Location (Including Location of Special Interest): Observational Follow-up</title>
          <description>The observational follow-up (OFU) was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. The neoplasms/cancer events of bladder, breast, colon, liver, pancreatic, prostate cancer, and melanoma were pre-specified as cancers of interest for the OFU. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any genitourinary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vaginal/vulvar</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon/rectal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gall bladder/biliary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal; not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hematologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (non-melanomatous)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (melanomatous)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Neurologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Due to the Indicated Cancer-related Event: Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any cancer-related death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="59"/>
                    <measurement group_id="O2" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon/rectal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gall bladder/biliary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal event; not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any genitourinary event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hematologic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (melanoma)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (non-melanomatous)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any neurologic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Died Due to the Indicated Cancer-related Event: Observational Follow-up</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any cancer-related death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any gastrointestinal event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon/rectal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gall bladder/biliary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal event; not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any genitourinary event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ovarian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any hematologic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (melanoma)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin (non-melanomatous)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Head and neck</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any neurologic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endocrine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Not specified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Bone Fracture Event – Overall and by Gender: Main Study and Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Bone Fracture Event – Overall and by Gender: Main Study and Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Bone Fracture Event – Overall and by Gender: Observational Follow-up</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Bone Fracture Event – Overall and by Gender: Observational Follow-up</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Overall, n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male, n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Female, n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined</title>
        <description>The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Main Study + Observational Follow-up Combined</title>
          <description>The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="81"/>
                    <measurement group_id="O2" value="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up</title>
        <description>The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Bone Fracture Event Reported as the Indicated Serious Adverse Event (by Higher Level Group Term) or Death: Observational Follow-up</title>
          <description>The OFU was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the OFU. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="35"/>
                    <measurement group_id="O2" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With an Event of Death Due to a Bone Fracture-related Event: Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Bone Fracture by Fracture Site: Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event, overall; n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="82"/>
                    <measurement group_id="O2" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="156"/>
                    <measurement group_id="O2" value="91"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb, any event, overall; n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="116"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb, any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="32"/>
                    <measurement group_id="O2" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb, any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb, any event, overall; n=2220, 222</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb, any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb, any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip, any event, overall; n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip, any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip, any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal, any event, overall; n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal, any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal, any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic, any event, overall; n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic, any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic, any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified, any event, overall; n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified, any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified, any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any event, overall; n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any event, male; n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any event, female; n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Bone Fracture by Fracture Site: Observational Follow-up</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event, overall; n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39"/>
                    <measurement group_id="O2" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb, any event, overall; n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb, any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb, any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23"/>
                    <measurement group_id="O2" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb, any event, overall; n=1280,1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb, any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal lower limb, any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip, any event, overall; n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip, any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur/hip, any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal, any event, overall; n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal, any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal, any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic, any event, overall; n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic, any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvic, any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified, any event, overall; n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified, any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unclassified, any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any event, overall; n=1280, 1250</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any event, male; n=665, 635</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other, any event, female; n=615, 615</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially High Morbidity Fractures: Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any event, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                    <measurement group_id="O2" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvis, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvis, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pelvis, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper leg, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper leg, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper leg, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vertebral event, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vertebral event, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any vertebral event, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar spine, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar spine, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar spine, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic spine, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic spine, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic spine, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervical spine, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervical spine, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervical spine, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Potentially High Morbidity Fracture Events and Non-high Morbidity Fracture Events, in Participants With Prior Hand/Upper Arm/Foot Fractures (H/UA/FF): Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The following bone fractures were grouped and were identified as potentially high morbidity bone fractures: hip, pelvis, upper leg, vertebral (lumbar spine, thoracic spine, cervical spine, spine - site unknown).</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any H/UA/FF event, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86"/>
                    <measurement group_id="O2" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any H/UA/FF event, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any H/UA/FF event, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High morbidity fractures, overall, n=2220, 2227</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High morbidity fractures, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>High morbidity fractures, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-high morbidity fractures, overall, n=2220, 222</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-high morbidity fractures, male, n=1142, 1152</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-high morbidity fractures, female, n=1078, 1075</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bone Fracture Events of the Indicated Cause: Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant.</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238"/>
                    <measurement group_id="O2" value="151"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-traumatic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="113"/>
                    <measurement group_id="O2" value="55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="110"/>
                    <measurement group_id="O2" value="77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pathologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Bone Fracture Events of the Indicated Cause: Observational Follow-up</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="64"/>
                    <measurement group_id="O2" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-traumatic event,</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Traumatic event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pathologic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
        <time_frame>From the beginning of the main study through the end of the observational follow-up (up to 11.4 years)</time_frame>
        <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Main Study and Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Main Study and Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bone Fracture Events With the Indicated Outcome: Main Study + Observational Follow-up Combined</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
          <population>ITT Population. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>bone fracture events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2220"/>
                <count group_id="O2" value="2227"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bone fracture events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="299"/>
                    <measurement group_id="O2" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal healing with standard management</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="250"/>
                    <measurement group_id="O2" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14"/>
                    <measurement group_id="O2" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional therapeutic measures required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="16"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Bone Fracture Events With the Indicated Outcome: Observational Follow-up</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Bone Fracture Events With the Indicated Outcome: Observational Follow-up</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. A bone fracture event is defined as one or more fractured bones occurring on the same date and that had the same Higher Level Group Term (HLGT) for fracture location, per participant. The indicated fracture outcome was pre-specified in the CRF and included &quot;Unknown&quot; as a category. Fracture events with missing outcome data were reported as &quot;Data unavailable.&quot;</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>bone fracture events</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Number of bone fracture events</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Unknown</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Normal healing with standard management</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Complication</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Additional therapeutic measures required</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Data unavailable</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="8"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up</title>
        <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
        <time_frame>From the end of the RECORD study through the end of the observational follow-up (up to 4.0 years)</time_frame>
        <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
        <group_list>
          <group group_id="O1">
            <title>Combined RSG: Observational Follow-up</title>
            <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion.</description>
          </group>
          <group group_id="O2">
            <title>Combined MET/SU: Observational Follow-up</title>
            <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Serious Adverse Event: Observational Follow-up</title>
          <description>The observational follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. At the end of the main study, all study medication was stopped. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator’s discretion. An SAE is defined as any event that is fatal; life threatening; disabling/incapacitating; results in hospitalization (excluding elective surgery or routine clinical procedures); prolongs a hospital stay; is associated with a congenital abnormality; cancer; is associated with an overdose. In addition, any event that the investigator regards as serious or that would suggest any significant hazard, contraindication, side effect, or precaution that may be associated with the study procedures should be reported as an SAE.</description>
          <population>Observational Follow-up Population: all participants from the ITT Population of the RECORD study who provided data during the observational follow-up. Analyses were performed by the original randomized treatment in the main RECORD study (referred to as Combined RSG and Combined MET/SU).</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1280"/>
                <count group_id="O2" value="1250"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any event</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99"/>
                    <measurement group_id="O2" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ankle fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Prostate cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung neoplasm malignant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Breast cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Basal cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Humerus fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Upper limb fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant melanoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Wrist fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hip fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Radius fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Forearm fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic neoplasm malignant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Foot fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Renal cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femur fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Femoral neck fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lumbar vertebral fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases to bone</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases to liver</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bladder cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Fall</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases to central nervous system</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rib fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Squamous cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brain neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastric neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases to lung</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Patella fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Abdominal pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute myeloid leukaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Acute respiratory failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Anaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Benign salivary gland neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary colic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bone neoplasm malignant</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Bronchial carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cardiac failure acute</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chest pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic lymphocytic leukaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Colon neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contusion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drowning</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Dysplasia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Endometrial cancer stage I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Leukaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lower limb fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung squamous cell carcinoma stage unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malignant neoplasm of pleura</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases to skin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases to testicle</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastatic renal cell carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Oesophageal carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Osteoarthritis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pancreatic necrosis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal cancer stage II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Spinal fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>T-cell lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Urinary tract infection</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Uterine leiomyosarcoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Biliary cancer metastatic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cervix carcinoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chronic obstructive pulmonary disease</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Comminuted fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Craniocerebral injury</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Gastrointestinal neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hepatic lesion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Joint dislocation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Laryngeal cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lip neoplasm malignant stage unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lung neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastases to lymph nodes</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Metastasis</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Musculoskeletal chest pain</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Myocardial infarction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Non-Hodgkin's lymphoma</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pubis fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pulmonary embolism</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal cancer recurrent</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Rectal neoplasm</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Skin ulcer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Small cell lung cancer stage unspecified</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sternal fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subdural haemorrhage</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Sudden death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thoracic vertebral fracture</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thyroid cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Vulval cancer</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>In the RECORD study (RS), SAEs were collected from BL through End of Study (up to 7.5 years); non-serious AEs were collected only for the randomized treatment period. SAEs were collected from the end of the RS through the end of OFU (up to 4.0 years).</time_frame>
      <desc>The Observational Follow-up was designed to collect data concerning cancer and bone fractures in RECORD participants during a 4-year period after the end of the main RECORD study. Other than bone fractures (tabulated in the Outcome Measure Module), no non-serious AEs were collected.</desc>
      <group_list>
        <group group_id="E1">
          <title>RSG in Addition to Background MET</title>
          <description>Participants inadequately controlled on background metformin (MET) were randomised to receive rosiglitazone (RSG), in addition to MET. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="E2">
          <title>SU in Addition to Background MET</title>
          <description>Participants inadequately controlled on background MET were randomised to receive, in addition to MET, a sulfonylurea (SU) (glibenclamide, gliclazide, or glimepiride). The SU was gradually increased to the maximum permitted dose (glibenclamide 15 mg per day or micronized equivalent of 10.5 mg per day; gliclazide 240 mg per day; glimepiride 4 mg per day) as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="E3">
          <title>RSG in Addition to Background SU</title>
          <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, RSG. RSG was initiated as a 4 mg once daily dose and was increased to a maximum dose of 8 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="E4">
          <title>MET in Addition to Background SU</title>
          <description>Participants inadequately controlled on background SU were randomised to receive, in addition to SU, MET. MET was gradually increased to the maximum permitted dose of 2550 mg per day as required to achieve a target HbA1c of less than or equal to 7.0 percent.</description>
        </group>
        <group group_id="E5">
          <title>Combined RSG: Observational Follow-up</title>
          <description>Participants randomized to receive RSG (MET+RSG and SU+RSG) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
        </group>
        <group group_id="E6">
          <title>Combined MET/SU: Observational Follow-up</title>
          <description>Participants randomized to the active control groups (MET+SU and SU+MET) in the main RECORD study. Participants were not provided with study medication in the observational follow-up; instead, anti-diabetic treatment was prescribed at the investigator's discretion.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="424" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="428" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="427" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="431" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="99" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="76" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Iron Deficiency Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypocoagulable State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Idiopathic Thrombocytopenic Purpura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Autoimmune Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemolytic Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="29" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="23" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Congestive</sub_title>
                <counts group_id="E1" subjects_affected="25" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Angina Pectoris</sub_title>
                <counts group_id="E1" subjects_affected="23" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="18" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Angina Unstable</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="18" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="14" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acute Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="19" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Coronary Artery Disease</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Myocardial Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Coronary Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arrythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acute Coronary Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis Coronary Artery</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Complete</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Arrest</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Aortic Valve Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sick Sinus Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Atrial Flutter</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Silent Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Mitral Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Atrial Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block Second Degree</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Failure Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiomegaly</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiovascular disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cor pulmonale</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Mitral Valve Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pericarditis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Right Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sinus Bradycardia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ventricular Arrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ventricular Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Congestive Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sinus Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tachyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Aortic Valve Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Coronary Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tachycardia Paroxysmal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Atrioventricular Block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bradyarrhythmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Flutter</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Adams-Stokes Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypertensive Cardiomyopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Left Ventricular Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Myocardial Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Supraventricular Extrasystoles</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tricuspid Valve Incompetence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Corneal Dystrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hydrocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Angiodysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Otosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sudden Hearing Loss</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vestibular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vestibular Neuronitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vertigo Positional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hyperparathyroidism Primary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Parathyroid Gland Enlargement</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Toxic Nodular Goitre</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Adrenal Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Basedow's Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="12" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Retinal Detachment</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Angle Closure Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Maculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Glaucoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cataract Nuclear</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Inflammation of Lacrimal Passage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Retinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vitreous Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Eye Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dacryostenosis Acquired</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Exudative Retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Macular Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Optic Atrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lens Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Retinal Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Umbilical Hernia</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Crohn's Disease</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colitis Ulcerative</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Duodenal ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric Polyps</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hiatus Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intestinal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diverticulum Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Faeces Discoloured</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastritis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intestinal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatic Pseudocyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peritoneal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Splenic Artery Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abdominal Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Anal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Appendicitis Perforated</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colonic Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colonic Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diverticular Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diverticulitis Intestinal Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Duodenal Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Mechanical Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Reflux Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Small Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abdominal Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastroduodenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatic Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatitis Necrotising</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Duodenal Fistula</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastroduodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatic necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peritonitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Salivary Gland Calculus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Barrett's oesophagus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Duodenitis Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Enterocele</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Enterocolitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Faecaloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haematemesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intestinal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intra-abdominal haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peptic Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Small Intestinal Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sudden Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Multi-Organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sudden Cardiac Death</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gait Disturbance</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hernia Obstructive</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Chest Discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Drowning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Brain Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dysplasia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cholecystitis Acute</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Biliary Colic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cholangitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cholecystitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bile Duct Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatic Steatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Jaundice Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatic Cirrhosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gallbladder Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cholestasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatitis Alcoholic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Cholecystectomy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Anaphylactic Reaction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pnuemonia</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pyelonephritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bronchopnuemonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abdominal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Procedural Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urosepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Localised Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abscess Intestinal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Appendiceal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bacterial Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Brochiectasis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Campylobacter Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cholecystitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Encephalitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Endocarditis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Herpes Zoster</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Infective Exacercbatn of Chronic Obstructive Airways Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Infective Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Joint Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Mastitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Myocardiac Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Osteomyelitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pelvic Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Phlebitis Infective</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Retroperitoneal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Toxoplasmosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Upper Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Viral Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arthritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Catheter Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Conjunctivitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Enteritis Infectious</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Groin Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Herpes Zoster Oticus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Infective Myositis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intestinal Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lyme Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Mastoiditis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Meningitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Necrotising Fasciitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Otitis Media Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatic Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peridiverticulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Periumbilical Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pneumococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pneumonia Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Procedural Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pyelonephritis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Scrotal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Staphylococcal Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pulmonary Tuberculosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Extradural Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatitis Viral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Infected Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pneumonia Legionella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pyelocystitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tracheobronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arteriosclerotic Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Blister Infected</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colostomy Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Gangrene</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ear Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastroenteritis Salmonella</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Herpes Ophthalmic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Keratitis herpetic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peritoneal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pyothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Subcutaneous Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title vocab="MedDRa">Splenic abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ankle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Humerus Fracture</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Radius Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rib Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Upper Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Head Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Joint Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Meniscus Lesion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Drug Toxicity</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Facial Bones Fracture</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Skin Laceration</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Incisional Hernia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Joint Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Procedural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Wound Dehiscence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Device Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Femoral Neck Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Accidental Overdose</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiac Valve Replacement Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cartilage Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Clavicle Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dislocation of Joint Prosthesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gun Shot Wound</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Limb Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lower Limb Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lumbar Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Injury</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Multiple Fractures</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Near Drowning</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Procedural Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Postoperative Ileus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Postoperative Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Skull Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acetabulum Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Anastomotic Leak</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Femur Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hand Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>In-Stent Arterial Restenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Multiple Injuries</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Muscle Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pelvic Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Spinal Compression Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Stent Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Traumatic Brain Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Spinal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tendon Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Brain Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Subdural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arthropod Sting</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Asbestosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cervical Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Epiphyseal Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Eyeball Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intentional Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Joint Sprain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Open Wound</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Procedural Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Shunt Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Synovial Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Wrist Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Fibula Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Limb Crushing Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Limb Traumatic Amputation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Operative Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Patella Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post Laminectomy Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Post-Traumatic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Postoperative Hernia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Traumatic Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Comminuted fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Craniocerebral injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pubis fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sternal fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Subdural haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood glucose Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Electrocardiogram T Wave Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Blood Pressure Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Liver Function Test Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Blood Creatinine Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Blood Urea Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Chest X-ray Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="17" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Foot</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemochromatosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypercalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hyperkalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypeonatraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Podagra</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypokalaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Increased Insulin Requirement</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="13" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dupuytren's Contracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metatarsalgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Spinal Osteoarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Amyotrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gouty Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Degeneration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Senile Osteoporosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rheumatic Fever</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rheumatoid Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Compartment Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Polymyalgia Rheumatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pain in Extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Exostosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Mobility Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Psoriatic Arthropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sacroiliitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Prostate Cancer</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Basal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colon cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Breast Cancer</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Breast Cancer Female</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Liver</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="4" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gallbladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal cancer</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Squamous Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colon Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Uterine Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thyroid Cancer</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bladder Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatic Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Myelodysplastic Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ovarian Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thyroid Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Endometrial Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Prostatic Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Angiomyolipoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Benign Salivary Gland Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Chronic Lymphocytic Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hairy Cell Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Abdominal Cavity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nasal Cavity Cancer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ovarian Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thyroid Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Transitional Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Abdominal Wall Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Adrenocortical Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bladder Transitional Cell carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Brain Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Breast Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Breast Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bronchial Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colon Cancer Stage III</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Epiglottic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Glioblastoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Lung</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Lymph Nodes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Myeloproliferative Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Non-Hodgkin's Lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Oesophageal Adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Oesophageal Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ovarian Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma Stage IV</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tonsil cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Uterine Leiomyosarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bladder Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Benign Lung Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lip Neoplasm Malignant Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Peritoneum</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastatic Malignant melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Neoplasm Prostate</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pharyngeal Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Skin Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vulval Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bile Duct Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cervix Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hair Follicle Tumour Benign</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hepatic Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Malignant Mesenchymoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Meningioma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Breast</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to Spine</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastatic Renal Cell Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ovarian Fibroma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal Adenoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Testicular Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tongue Neoplasm Malignant Stage Unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acute myeloid leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Biliary neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bone neoplasm malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Endometrial cancer stage I</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Leukaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung squamous cell carcinoma stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Malignant neoplasm of pleura</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to skin</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastases to testicle</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal cancer stage II</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>T-cell lymphoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Biliary cancer metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Gastrointestinal neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Laryngeal cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metastasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectal cancer recurrent</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Small cell lung cancer stage unspecified</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebrovascular Accident</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="24" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="11" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Carotid Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Syncope Vasovagal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Carpal Tunnel syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Facial Paresis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Global Amnesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hemiparesis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cognitive Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vertebrobasilar Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemorrhage Intracranial</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hemiplegia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intracranial Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Multiple Sclerosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vascular Dementia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vascular Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Demyelination</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypoxic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ischaemic Cerebral Infarction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Normal Pressure Hydrocephalus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Paralysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Paraparesis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Reversible Ischaemic Neurological Deficit</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ruptured Cerebral Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tension Headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Brain Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1112"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cervicobrachial Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypertonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Polyneuropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Radiculitis lumbosacral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Carotid Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cerebral Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cerebrovascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Facial Palsy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypertensive Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypokinesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lumbar Radiculopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metabolic Encephalopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nerve Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nerve Root Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Parkinsonism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion Spontaneous</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Alcohol Abuse</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Suicide Attempt</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Mania</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bipolar Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title vocab="MedDRa">Completed Suicide</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dysthymic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title vocab="MedDRa">Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title vocab="MedDRa">Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Colic</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Calculus Ureteric</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Calculus Urinary</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cystitis Noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acute Prerenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hydronephrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urethral Fistula</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urinary Bladder Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bladder Perforation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Nephropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urinary Tract Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Albuminuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Calculus Bladder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urinary Tract Inflammation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Azotaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Calculus Urethral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ketonuria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Renal Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urine Flow Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Benign Prostatic Hyperplasia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Uterine Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cystocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Rectocele</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Breast Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cervical Polyp</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Endometrial Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Menometrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peyronie's Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Testicular Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vaginal Prolapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Fibrocystic Breast Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Metrorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vaginal Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Uterine Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Orchitis Noninfective</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pelvic Peritoneal Adhesions</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Postmenopausal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Prostatic Obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vulvovaginal Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Prostatism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vaginal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vaginal Polyp</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Vulval Leukoplakia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Sleep Apnoea Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bronchitis Chronic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nasal Polyps</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nasal Septum Deviation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Alveolitis Fibrosing</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pulmonary Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Respiratory Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dyspnoea Exertional</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Consolidation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nasal Turbinate Hypertrophy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Tracheal Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lung Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pulmonary Fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acute Pulmonary Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dysnoea Paroxysmal Nocturnal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Nocturnal Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pleuritic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hydrothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Respiratory Alkalosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Drug Eruption</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Skin Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dermatitis Allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Decubitus Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Skin Lesion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lichen Planus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pityriasis Rubra Pilaris</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="10" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Aortic Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Intermittent Claudication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Varicose Vein</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Essential Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypovolaemic Shock</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Femoral Artery Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypertensive Crisis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Iliac Artery Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Accelerated Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis obliterans</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Artery Dissection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Orthostatic Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Shock Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Aortic Aneurysm Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arterial Stenosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Cardiovascular Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Extremity Necrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Femoral Arterial Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Labile Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Malignant Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peripheral Arterial Occlusive Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Peripheral Vascular Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis Superficial</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Venous Insufficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arterial Thrombosis Limb</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Angiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arterial Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Lymphoedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Venous Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic Microangiopathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1117" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="1105" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="1103" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="1122" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="105" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="55" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="38" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="67" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic retinopathy</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="51" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="61" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="81" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="44" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="135" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="144" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="133" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="41" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="216" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="202" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="121" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="122" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="139" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="128" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="136" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="122" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" subjects_affected="110" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="129" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="106" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="88" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="66" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="59" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="49" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="55" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="56" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="40" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="236" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="144" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="193" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="120" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="190" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="162" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="144" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" subjects_affected="121" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="78" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="155" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="64" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" subjects_affected="51" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="97" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="49" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="68" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="81" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="57" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="153" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="143" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="95" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="105" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="119" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="126" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="98" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="70" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="67" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="54" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="102" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="82" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="62" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="50" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="66" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="61" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="58" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="47" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="60" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="46" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="42" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
              <event>
                <sub_title>Diabetic neuropathy</sub_title>
                <counts group_id="E1" subjects_affected="54" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="53" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="87" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="63" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="47" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="35" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="81" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="79" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="61" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="51" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="345" subjects_at_risk="1117"/>
                <counts group_id="E2" subjects_affected="372" subjects_at_risk="1105"/>
                <counts group_id="E3" subjects_affected="302" subjects_at_risk="1103"/>
                <counts group_id="E4" subjects_affected="319" subjects_at_risk="1122"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="1280"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="1250"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

